The Research Division of Cardiology Assoc. of Fairfield County

The Research Division of Cardiology Assoc. of Fairfield CountyThe Research Division of Cardiology Assoc. of Fairfield CountyThe Research Division of Cardiology Assoc. of Fairfield County

The Research Division of Cardiology Assoc. of Fairfield County

The Research Division of Cardiology Assoc. of Fairfield CountyThe Research Division of Cardiology Assoc. of Fairfield CountyThe Research Division of Cardiology Assoc. of Fairfield County
  • Home
  • Podcasts
  • Research
  • Documents
  • About Us
  • Contact Us
  • FuturePulse Apple Podcast
  • PatientPulse ApplePodcast
  • EVOLVE-MI
  • PREVAIL
  • SURMOUNT-MMO
  • OCEAN(a) Lp(a)
  • More
    • Home
    • Podcasts
    • Research
    • Documents
    • About Us
    • Contact Us
    • FuturePulse Apple Podcast
    • PatientPulse ApplePodcast
    • EVOLVE-MI
    • PREVAIL
    • SURMOUNT-MMO
    • OCEAN(a) Lp(a)

  • Home
  • Podcasts
  • Research
  • Documents
  • About Us
  • Contact Us
  • FuturePulse Apple Podcast
  • PatientPulse ApplePodcast
  • EVOLVE-MI
  • PREVAIL
  • SURMOUNT-MMO
  • OCEAN(a) Lp(a)

Current research activity

Weight Loss / Cardiovascular Risk Reduction

 SURMOUNT-MMO GLP1-RA for weight loss in patients without diabetes and increased cardiovascular risk.  Enrollment to begin soon.


Coronary Artery Disease/Dyslipidemia Trials

 Evolve-MI (Amgen) Phase IV • Evolucumab + statin vs standard of care early after MI (STEMI/ACS NSTEMI).  Open label  


 PREVAIL (New Amsterdam Pharma) Phase III • Obicetrapib (CETP inhibitor) vs placebo PO Daily for patients with ASCVD and LDL chol >70  


 Oceans(a) (Amgen) Phase III • Olparsiran vs standard of care early after treatment of Lipoprotein a (Lp(a)) in patgients with h/o MI or high risk patietns after PCI.  Double blind placebo controlled study.


 VICTORION-INCEPTION (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care for patients with recent acute coronary syndrome 


 ORION-4 (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Placebo; examining outcomes in subjects with heart attack or stroke 


 VICTORION-INITIATE (Novartis)- Phase III • (*no longer enrolling*) Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care; assessing an “inclisiran-first” strategy in an ASCVD population 


 VESALIUS-CV (Amgen)- Phase III (*no longer enrolling*) • Evolocumab (monoclonal antibody, PCSK9 inhibitor) vs. Placebo; assessing the effect of evolocumab on major cardiovascular events in adults with prior heart attack or stroke 


Arrhythmia Trials

 OCEANIC-AF (Bayer) Phase III • Asundexian (FXIa inhibitor) vs. apixaban for patients with atrial fibrillation.

 RAPID (Milestone)- Phase III • Etripamil (novel intra-nasal verapamil analogue) vs. Placebo for the rapid termination of PSVT episodes 

 AZALEA (Anthos/TIMI)- Phase II (*no longer enrolling*) • Abelacimab (subcutaneous monoclonal antibody) vs. Rivaroxaban; assessing the bleeding profile of abelacimab in patients with AF with moderate-to-high risk of stroke o Paroxysmal Supraventricular Tachycardia


Aortic Valve Regurgitation & Stenosis Trials

 Expand TAVR II (Medtronic) • Evolut™ PRO and Evolut™ PRO+ Device in patients with moderate AS and Class II-III heart failure.


 Optimize PRO (Medtronic) • (*no longer enrolling*) Evolut™ PRO and Evolut™ PRO+ Device Trial examining valve performance & procedural outcomes associated with an “optimized” TAVR (transcatheter aortic valve replacement) care pathway & post-TAVR conduction disturbance pathway


Mitral Regurgitation & Stenosis Trials

 EXPAND G4 (Abbott) (*no longer enrolling*) • MitraClip device trial evaluating outcomes & characterizing trends in patient selection 


Heart Failure Trials

 DAPA ACT HF (AstraZeneca) • Phase IV o Dapagliflozin vs. Placebo; examining outcomes from in-hospital initiation in acute heart failure o Heart Failure with Preserved Ejection Fraction & Obesity 


 GPID SUMMIT (Eli Lilly)- Phase III • Tirzepatide (GIP & GLP-1 agonist) vs. Placebo in obese patients with chronic heart failure with preserved ejection fraction  


Hypertension Trials

 RADIANCE II (Recor)  • Paradise System device trial examining the effects of ultrasound renal denervation in subjects with medication-resistant hypertension 

Copyright © 2022 FuturePulse Thomas Nero MD- All Rights Reserved.

Powered by GoDaddy

Help us undestand

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept